DHR-N 2.34 GE-N 4.09 AMZN-Q -0.22 SES-T 0.48 UBER-N 3.39 BN-T 1.72 HPS.A-T 1.34
ConjuChem Inc (CJB-T)

ConjuChem Inc (CJB-T)

0 watching

0.00
0.00 (0.00%) 1d
0

Related posts

Nervous markets await Nvidia
DON'T BUY

ConjuChem Inc(CJB-T)

Nov 26, 2007
Thinks it’s a horrible company. Last year they did $120 million of financing at $0.65. The $1 stock immediately plunged to $0.65. Last week they announced a $20 million financing at $0.15 convertible debenture. Has gone through $120 million in 12 months.
Peter HodsonPeter Hodson
No
Unlock Rating
$0.130

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

ConjuChem Inc(CJB-T)

Apr 07, 2005
Thinks it will bounce around a little bit. Not his favourite name. Continue to spend a lot of money and ultimately will have to come back to the market, perhaps some time next year. With the state of biotechs, both large and small, it is not a sector he would want to be in right now. Doesn't like the management.
Peter HodsonPeter Hodson
No
Unlock Rating
$3.750

Stock price when the opinion was issued

biotechnology pharmaceutical
WEAK BUY

ConjuChem Inc(CJB-T)

Feb 07, 2005
Had a problem with nausea on their drug. Data is improving. Starting to fix the nausea problem. A very effective product. Did another financing, so they are well cashed up. Not the best management team.
Peter HodsonPeter Hodson
No
Unlock Rating
$4.700

Stock price when the opinion was issued

biotechnology pharmaceutical
WAIT

ConjuChem Inc(CJB-T)

Jan 06, 2005
Was concerned when their drug was causing nausea, so they sold. Thinks they will have to do a lot of work. Will watch to see if they can solve the problem.
Werner MuehelemannWerner Muehelemann
No
Unlock Rating
$4.910

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

ConjuChem Inc(CJB-T)

Nov 04, 2004
The nausea under the diabetes drug is fixable under certain conditions, but the question is can the do it. If they can fix, it's a very robust product and will have a very big market.
Peter HodsonPeter Hodson
No
Unlock Rating
$3.490

Stock price when the opinion was issued

biotechnology pharmaceutical
WAIT

ConjuChem Inc(CJB-T)

Sep 24, 2004
Sold his holdings because of the convertible debenture issued. Too early to go back in. Expect their will be a lot of tax selling towards the end of the year and will look at it at that time.
Peter HodsonPeter Hodson
No
Unlock Rating
$2.800

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

ConjuChem Inc(CJB-T)

Sep 08, 2004
The drop out rate on their diabetes drug was higher than expected. Wasn't happy the way management disseminated the information. Dead money in the near term.
Andrew McCreathAndrew McCreath
No
Unlock Rating
$3.400

Stock price when the opinion was issued

biotechnology pharmaceutical
WEAK BUY

ConjuChem Inc(CJB-T)

Aug 23, 2004
Feels there is a potential drug here. Probably is near its bottom. A fair risk/reward. They are trying a new formulation re: nausea of the drugs they tested in phase 2 trials. Also waiting for a combination trial.
Martin Hubbes, CFAMartin Hubbes, CFA
Owned
Unlock Rating
$3.990

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

ConjuChem Inc(CJB-T)

Aug 06, 2004
Needs to know more before he would buy. Have to see better results in the future. Buy when it's rising.
Bruce Campbell (1)Bruce Campbell (1)
No
Unlock Rating
$3.610

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

ConjuChem Inc(CJB-T)

Jul 30, 2004
Not really happy with management. Took a big drop and is an interesting buy now. The drug works. Potential of being in phase three next year. Really cheap.
Ed HoEd Ho
Owned
Unlock Rating
$3.990

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

ConjuChem Inc(CJB-T)

Jul 28, 2004
Not sure you should buy it at this time. You want to hold it when there is a possibility of approval being given for their product.
Michael SmedleyMichael Smedley
Owned
Unlock Rating
$4.270

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

ConjuChem Inc(CJB-T)

Jul 15, 2004
A negative report on patient's reactions created a drop in the stock. Drugs in phase one or phase two trials can be very volatile. Prefers larger companies.
David DriscollDavid Driscoll
No
Unlock Rating
$4.800

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

ConjuChem Inc(CJB-T)

Jul 08, 2004
An announcement is coming out next week and he thinks the news will be good, but would like it to be great. Speculative. Good management and balance sheet.
Peter HodsonPeter Hodson
Owned
Unlock Rating
$11.500

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

ConjuChem Inc(CJB-T)

May 12, 2004
Stock has come off since they announced the successful trials on their diabetes applications. There is some risk, but has potential.
Michael SmedleyMichael Smedley
Owned
Unlock Rating
$11.720

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

ConjuChem Inc(CJB-T)

Apr 22, 2004
Has had a huge move. Has moved too far, too fast. Solid programs. Expensive.
Glenn Paradis, BA, CFAGlenn Paradis, BA, CFA
No
Unlock Rating
$13.800

Stock price when the opinion was issued

biotechnology pharmaceutical
Showing 1 to 15 of 23 entries
Next PageNext Page

ConjuChem Inc(CJB-T) Rating

Ranking : 1 out of 5

Star iconStar empty iconStar empty iconStar empty iconStar empty icon

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for ConjuChem Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

ConjuChem Inc(CJB-T) Frequently Asked Questions

What is ConjuChem Inc stock symbol?

ConjuChem Inc is a OTC stock, trading under the symbol CJB-T on the (). It is usually referred to as or CJB-T

Is ConjuChem Inc a buy or a sell?

In the last year, there was no coverage of ConjuChem Inc published on Stockchase.

Is ConjuChem Inc a good investment or a top pick?

ConjuChem Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for ConjuChem Inc.

Why is ConjuChem Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is ConjuChem Inc worth watching?

In the last year 0 stock analysts on Stockchase covered ConjuChem Inc. The stock is worth watching.

What is ConjuChem Inc stock price?

On , ConjuChem Inc (CJB-T) stock closed at a price of $.

Build our watch list

Sign in to track investments
you care about

Latest Buy Signals

CJT-T 0.41$84.44
META-Q 24.81$597.02
EXC-N -0.12$46.48
SHAK-N 5.66$94.37
ABT-N 1.94$132.82

Today's Top Picks

DHR-N 2.34$199.05
GE-N 4.09$207.7
AMZN-Q -0.22$189.98
SES-T 0.48$13.64
UBER-N 3.39$84.28

Popular Articles

Latest Sell Signals

BIP.UN… 1$42.71
HSBC-N 1.38$56.51
INTC-Q 0.64$20.62
T-T -0.38$20.72
AC-T 0.58$14.69

Most Recent Experts

Stockchase Insights

Stockchase Insights

5i Research

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Dan Rohinton

Dan Rohinton

iA Global Asset Management

Richard Fogler

Richard Fogler

Kingwest & Company

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

© Stockchase Inc.